Evaluating Next Generation Live Attenuated TB Vaccine Candidates (Old ID 27396)

Bill & Melinda Gates Foundation
Role

Principal Investigator

Description

A key strategic goal of the BMGF Global Heatlh TB team is to prevent M. tuberculosis infection and/or TB disease through vaccination to decrease the morbidity public health burden of this epidemic. One pillar of this strategy is to accelerate development of a robust pipeline of 'next generation' candidates. This investment will evaluate novel vaccine candidates that belong to the important platform of live, attenuated mycobacterial strains. Using a head-to-head comparison ion a standardized mouse model of TB, this invesment aims to contribute to that pipeline by identifying a lead live, attenuated mycobacterial candidate(s) for further evaluation and potential development. This head-to-head comparison includes our own vaccine candidate covered by JCU IP.

Date

01 Oct 2021 - 30 Jun 2025

Project Type

GRANT

Keywords

Mycobacterium tuberculosis;Bcg;Vaccine Development;Immunology;Infectious disease

Funding Body

Bill & Melinda Gates Foundation

Amount

2389557.12

Project Team

N/A